
Tianjin Medical Journal ›› 2023, Vol. 51 ›› Issue (3): 311-314.doi: 10.11958/20221108
• Clinical Research • Previous Articles Next Articles
FENG Songqiao(
), HE Yewei, WANG Yan
Received:2022-07-14
Revised:2022-10-31
Published:2023-03-15
Online:2023-03-02
FENG Songqiao, HE Yewei, WANG Yan. Expression levels of plasma SIRT-1 and syndecan-1 in patients with sepsis-induced ALI/ARDS and their effect on prognosis[J]. Tianjin Medical Journal, 2023, 51(3): 311-314.
CLC Number:
| 组别 | n | SIRT-1 | syndecan-1 |
|---|---|---|---|
| 对照组 | 50 | 1.42±0.36 | 211.24±57.26 |
| ALI/ARDS组 | 106 | 0.81±0.27 | 501.67±81.32 |
| t | 11.790** | 22.719** |
Tab.1 Comparison of plasma SIRT-1 and syndecan-1 levels between the ALI/ARDS group and the control group
| 组别 | n | SIRT-1 | syndecan-1 |
|---|---|---|---|
| 对照组 | 50 | 1.42±0.36 | 211.24±57.26 |
| ALI/ARDS组 | 106 | 0.81±0.27 | 501.67±81.32 |
| t | 11.790** | 22.719** |
| 组别 | n | 男性 | 年龄 (岁) | BMI (kg/m2) | 原发疾病 | APACHEⅡ (分) | LIS (分) | SIRT-1 (μg/L) | syndecan-1 (μg/L) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 呼吸道感染 | 尿路感染 | 腹腔感染 | 其他 | |||||||||
| 生存组 | 66 | 36(54.55) | 56.71±9.42 | 22.25±2.31 | 30(45.45) | 14(21.21) | 12(18.18) | 10(15.15) | 19.89±6.42 | 1.98±0.22 | 0.96±0.27 | 451.19±72.35 |
| 死亡组 | 40 | 25(62.50) | 58.04±9.89 | 22.01±2.08 | 22(55.00) | 8(20.00) | 7(17.50) | 3(7.50) | 28.43±9.33 | 2.28±0.25 | 0.56±0.22 | 584.97±90.31 |
| t | 0.645 | 0.691 | 0.538 | 1.676 | 5.570** | 6.246** | 7.909** | 8.391** | ||||
Tab.2 Comparison of relevant indicators between the survival group and the death group
| 组别 | n | 男性 | 年龄 (岁) | BMI (kg/m2) | 原发疾病 | APACHEⅡ (分) | LIS (分) | SIRT-1 (μg/L) | syndecan-1 (μg/L) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 呼吸道感染 | 尿路感染 | 腹腔感染 | 其他 | |||||||||
| 生存组 | 66 | 36(54.55) | 56.71±9.42 | 22.25±2.31 | 30(45.45) | 14(21.21) | 12(18.18) | 10(15.15) | 19.89±6.42 | 1.98±0.22 | 0.96±0.27 | 451.19±72.35 |
| 死亡组 | 40 | 25(62.50) | 58.04±9.89 | 22.01±2.08 | 22(55.00) | 8(20.00) | 7(17.50) | 3(7.50) | 28.43±9.33 | 2.28±0.25 | 0.56±0.22 | 584.97±90.31 |
| t | 0.645 | 0.691 | 0.538 | 1.676 | 5.570** | 6.246** | 7.909** | 8.391** | ||||
| 变量 | β | SE | Wald χ2 | P | OR(95%CI) |
|---|---|---|---|---|---|
| APACHEⅡ | 0.542 | 0.245 | 4.894 | 0.027 | 1.719(1.064~2.779) |
| LIS | 0.767 | 0.284 | 7.294 | 0.007 | 2.153(1.234~3.757) |
| SIRT-1 | -0.271 | 0.118 | 5.274 | 0.022 | 0.763(0.605~0.961) |
| syndecan-1 | 0.891 | 0.321 | 7.705 | 0.006 | 2.438(1.299~4.573) |
| 常数项 | 0.357 | 0.174 | 4.210 | 0.040 | 1.429 |
Tab.3 Analysis of influence factors for death in patients with ALI/ARDS
| 变量 | β | SE | Wald χ2 | P | OR(95%CI) |
|---|---|---|---|---|---|
| APACHEⅡ | 0.542 | 0.245 | 4.894 | 0.027 | 1.719(1.064~2.779) |
| LIS | 0.767 | 0.284 | 7.294 | 0.007 | 2.153(1.234~3.757) |
| SIRT-1 | -0.271 | 0.118 | 5.274 | 0.022 | 0.763(0.605~0.961) |
| syndecan-1 | 0.891 | 0.321 | 7.705 | 0.006 | 2.438(1.299~4.573) |
| 常数项 | 0.357 | 0.174 | 4.210 | 0.040 | 1.429 |
| 指标 | AUC及95%CI | 截断值 | 敏感度 (%) | 特异度 (%) | 约登 指数 |
|---|---|---|---|---|---|
| APACHEⅡ | 0.756(0.661~0.851) | 24分 | 75.00 | 71.21 | 0.462 |
| LIS | 0.762(0.668~0.855) | 2分 | 57.50 | 86.36 | 0.439 |
| SIRT-1 | 0.860(0.791~0.930) | 0.77 μg/L | 77.50 | 84.85 | 0.624 |
| syndecan-1 | 0.870(0.800~0.940) | 495.75 μg/L | 82.50 | 81.82 | 0.643 |
Tab.4 Evaluation value analysis of each index to prognosis of ALI/ARDS patients
| 指标 | AUC及95%CI | 截断值 | 敏感度 (%) | 特异度 (%) | 约登 指数 |
|---|---|---|---|---|---|
| APACHEⅡ | 0.756(0.661~0.851) | 24分 | 75.00 | 71.21 | 0.462 |
| LIS | 0.762(0.668~0.855) | 2分 | 57.50 | 86.36 | 0.439 |
| SIRT-1 | 0.860(0.791~0.930) | 0.77 μg/L | 77.50 | 84.85 | 0.624 |
| syndecan-1 | 0.870(0.800~0.940) | 495.75 μg/L | 82.50 | 81.82 | 0.643 |
| [1] | LONG M E, MALLAMPALLI R K, HOROWITZ J C. Pathogenesis of pneumonia and acute lung injury[J]. Clin Sci (Lond), 2022, 136(10):747-769. doi:10.1042/CS20210879. |
| [2] | MCVEY M J, STEINBERG B E, GOLDENBERG N M. Inflammasome activation in acute lung injury[J]. Am J Physiol Lung Cell Mol Physiol, 2021, 320(2):L165-L178. doi:10.1152/ajplung.00303.2020. |
| [3] | MOKRA D. Acute lung injury-from pathophysiology to treatment[J]. Physiol Res, 2020, 69(Suppl 3):S353-S366. doi:10.33549/physiolres.934602. |
| [4] | CHEN C, ZHOU M, GE Y, et al. SIRT1 and aging related signaling pathways[J]. Mech Ageing Dev, 2020, 187(4):111215. doi:10.1016/j.mad.2020.111215. |
| [5] | 赵维, 刘俊彦, 李玉英. SIRT1减弱对脂多糖致急性呼吸窘迫综合征小鼠的促炎作用[J]. 中华肺部疾病杂志(电子版), 2017, 10(2):163-167. |
| ZHAO W, LIU J Y, LI Y Y. Effect of SIRT1 weakening on inflammation in mice with acute respiratory distress syndrome induced by lipopolysaccharide[J]. Chin J Lung Dis(Electronic Edition), 2017, 10(2):163-167. doi:10.3877/cma.j.issn.1674-6902.2017.02.010. | |
| [6] | RANGARAJAN S, RICHTER J R, RICHTER R P, et al. Heparanase-enhanced shedding of syndecan-1 and its role in driving disease pathogenesis and progression[J]. J Histochem Cytochem, 2020, 68(12):823-840. doi:10.1369/0022155420937087. |
| [7] | LAMBERT J, MAKIN K, AKBAREIAN S, et al. ADAMTS-1 and syndecan-4 intersect in the regulation of cell migration and angiogenesis[J]. J Cell Sci, 2020, 133(7):jcs235762. doi:10.1242/jcs.235762. |
| [8] | SHANKAR-HARI M, PHILLIPS G S, LEVY M L, et al. Developing a new definition and assessing new clinical criteria for septic shock: for the third international consensus definitions for sepsis and septic shock (Sepsis-3)[J]. JAMA, 2016, 315(8):775-787. doi:10.1001/jama.2016.0289. |
| [9] | 中华医学会重症医学分会. 急性肺损伤/急性呼吸窘迫综合征诊断和治疗指南(2006)[J]. 中华急诊医学杂志, 2007, 16(4):343-349. |
| Critical Care Branch of CMA. Guidelines for diagnosis and treatment of acute lung injury/acute respiratory distress syndrome(2006)[J]. Chin J Emerg Med, 2007, 16(4):343-349. doi:10.3760/j.issn:1671-0282.2007.04.002. | |
| [10] | SONG H, CHEN Q, XIE S, et al. GDF-15 prevents lipopolysaccharide-mediated acute lung injury via upregulating SIRT1[J]. Biochem Biophys Res Commun, 2020, 526(2):439-446. doi:10.1016/j.bbrc.2020.03.103. |
| [11] | FU C, HAO S, XU X, et al. Activation of SIRT1 ameliorates LPS-induced lung injury in mice via decreasing endothelial tight junction permeability[J]. Acta Pharmacol Sin, 2019, 40(5):630-641. doi:10.1038/s41401-018-0045-3. |
| [12] | YANG F, YAN J, LU Y, et al. MicroRNA-499-5p targets SIRT1 to aggravate lipopolysaccharide-induced acute lung injury[J]. Free Radic Res, 2021, 55(1):71-82. doi:10.1080/10715762.2020.1863393. |
| [13] | YANG Y, LI L. Depleting microRNA-146a-3p attenuates lipopolysaccharide-induced acute lung injury via up-regulating SIRT1 and mediating NF-κB pathway[J]. J Drug Target, 2021, 29(4):420-429. doi:10.1080/1061186X.2020.1850738. |
| [14] | LEI J, SHEN Y, XV G, et al. Aloin suppresses lipopolysaccharide-induced acute lung injury by inhibiting NLRP3/NF-κB via activation of SIRT1 in mice[J]. Immunopharmacol Immunotoxicol, 2020, 42(4):306-313. doi:10.1080/08923973.2020.1765373. |
| [15] | AN N, YANG T, ZHANG X X, et al. Bergamottin alleviates LPS-induced acute lung injury by inducing SIRT1 and suppressing NF-κB[J]. Innate Immun, 2021, 27(7/8):543-552. doi:10.1177/17534259211062553. |
| [16] | SOLIMAN N A, YUSSIF S M, SHEBL A M. Syndecan-1 could be added to hormonal receptors and HER2/neu in routine assessment of invasive breast carcinoma, relation of its expression to prognosis and clinicopathological parameters[J]. Pathol Res Pract, 2019, 215(5):977-982. doi:10.1016/j.prp.2019.02.003. |
| [17] | IBA T, LEVY J H. Derangement of the endothelial glycocalyx in sepsis[J]. J Thromb Haemost, 2019, 17(2):283-294. doi:10.1111/jth.14371. |
| [18] | 齐颖, 李真玉, 王斌, 等. Wnt5a与Syndecan-1在小鼠脓毒症致急性肺损伤中的表达研究[J]. 中国急救医学, 2017, 37(1):43-48,封3. |
| QI Y, LI Z Y, WANG B, et al. The expression and significance of Wnt5a and Syndecan-1 in sepsis-induced acute lung injury of mice[J]. Chin J Crit Care Med, 2017, 37(1):43-48,Cover 3. doi:10.3969/j.issn.1002-1949.2017.01.010. | |
| [19] | LI H, HAO Y, YANG L L, et al. MCTR1 alleviates lipopolysaccharide-induced acute lung injury by protecting lung endothelial glycocalyx[J]. J Cell Physiol, 2020, 235(10):7283-7294. doi:10.1002/jcp.29628. |
| [20] | VIGNON P, EVRARD B, ASFAR P, et al. Fluid administration and monitoring in ARDS: which management?[J]. Intensive Care Med, 2020, 46(12):2252-2264. doi:10.1007/s00134-020-06310-0. |
| [21] | KAJITA Y, TERASHIMA T, MORI H, et al. A longitudinal change of syndecan-1 predicts risk of acute respiratory distress syndrome and cumulative fluid balance in patients with septic shock: A preliminary study[J]. J Intensive Care, 2021, 9(1):27. doi:10.1186/s40560-021-00543-x. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||